NPI: 1194261594 · JUNEAU, AK 99801 · Community/Behavioral Health Agency · NPI assigned 01/10/2017
Authorized official HARRIS, DANIEL controls 20+ related entities in our dataset. Read more
| Authorized Official | HARRIS, DANIEL (CHIEF FINANCIAL OFFICER) |
| NPI Enumeration Date | 01/10/2017 |
Other providers sharing the same authorized official: HARRIS, DANIEL
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 575 | $207K |
| 2019 | 1,364 | $432K |
| 2020 | 1,163 | $464K |
| 2021 | 1,188 | $444K |
| 2022 | 19,778 | $12.92M |
| 2023 | 6,091 | $4.35M |
| 2024 | 1,651 | $1.06M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 20,789 | 1,124 | $15.15M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3,054 | 2,532 | $2.12M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2,216 | 1,584 | $1.34M |
| H2021 | Community-based wrap-around services, per 15 minutes | 709 | 329 | $528K |
| 80305 | 1,852 | 1,252 | $169K | |
| T1016 | Case management, each 15 minutes | 364 | 163 | $156K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 122 | 82 | $64K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 136 | 118 | $59K |
| 0011A | 61 | 61 | $45K | |
| 99442 | 118 | 60 | $44K | |
| 80306 | 77 | 39 | $37K | |
| 0012A | 49 | 47 | $34K | |
| 80053 | Comprehensive metabolic panel | 56 | 54 | $25K |
| 0001A | 32 | 32 | $24K | |
| 0002A | 23 | 23 | $18K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 79 | 72 | $17K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | 138 | 86 | $17K |
| G0467 | Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 371 | 272 | $14K |
| H0001 | Alcohol and/or drug assessment | 26 | 14 | $11K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 281 | 175 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 13 | 13 | $3K |
| 91300 | 80 | 79 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 41 | 38 | $0.00 |
| 86708 | 56 | 53 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 409 | 223 | $0.00 |
| 93268 | 91 | 50 | $0.00 | |
| 91301 | 112 | 109 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 53 | 50 | $0.00 |
| 86580 | 117 | 92 | $0.00 | |
| 86592 | 55 | 52 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 87 | 66 | $0.00 |
| 87340 | 56 | 53 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 20 | 18 | $0.00 |
| 86317 | 54 | 51 | $0.00 | |
| 90686 | 13 | 13 | $0.00 |